Skip to main content

Table 2 Characteristics of the 15 Cavitary Adenocarcinoma patients with EGFR mutations

From: Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Patient No. Age, y Gender Smoking Stage Tumor size Wall EGFR mutations EGFR-TKI PFS, mo Efficacy T790 M
1 62 Male Never IV 2.6 cm Thick L858R mutation Erlotinib 4.7 SD Unknown
2 71 Male Never IV 3.6 cm Thick L858R mutation Gefitinib 3.3 PR Negative
3 52 Female Never IV 2.2 cm Thick L858R mutation Gefitinib 6.0 PR Negative
4 44 Male Never IV 2.4 cm Thick L858R mutation Gefitinib 9.6 PR Positive
5 57 Male Never IV 2.0 cm Thick L858R mutation Gefitinib 1.0 PD Negative
6 50 Male Smoker IV 2.6 cm Thick L858R mutation Erlotinib 4.2 SD Unknown
7 76 Female Never IV 5.0 cm Thick Exon 19 deletion Gefitinib 5.2 SD Unknown
8 37 Female Never IV 2.8 cm Thin Exon 19 deletion Icotinib 11.4 PR Unknown
9 75 Male Never IV 2.2 cm Thin Exon 19 deletion Icotinib 11.0 PR Positive
10 61 Female Never IV 2.2 cm Thin Exon 19 deletion Gefitinib 24.5 PR Positive
11 47 Male Smoker IV 4.5 cm Thick Exon 19 deletion Gefitinib 6.7 PR Negative
12 48 Male Never IV 2.2 cm Thick Exon 19 deletion Gefitinib 6.5 SD Negative
13 51 Male Smoker IV 4.8 cm Thin Exon 19 deletion Icotinib 9.7 SD Negative
14 56 Female Never Recurrent 2.0 cm Thin Exon 19 deletion Gefitinib 4.5 PR Positive
15 39 Male Smoker IV 2.5 cm Thin Exon 19 deletion Icotinib 3.0 SD Unknown
  1. Abbreviations: EGFR-TKI epidermal growth factor receptor- tyrosine kinase inhibitor, ECOG PS Eastern Corporation Oncology Group performance status, SD standard deviation, PR partial response, SD stable disease, PD progressive disease, PFS median progression-free survival